

Lumryz EXTENDED-RELEASE (sodium oxybate) for extended-release oral suspension © 4.5 | 6 | 7.5 | 9 g

FOR PEOPLE 7 YEARS OR OLDER WITH **NARCOLEPSY** TO TREAT **CATAPLEXY** OR **EDS**

WELCOME TO
5:23 PM

**IF YOU HAVE NARCOLEPSY,
EXTENDED-RELEASE LUMRYZ®
CAN HELP YOU FEEL AWAKE
FOR MORE DAYTIME MOMENTS**

"The golden hour. I've wanted to paint this moment. The sun sits on the horizon, bathing the world in warm, red light that feels alive, and the world is at peace."

—Wendy,
living with narcolepsy and treating with **LUMRYZ**

Wendy was compensated by Alkermes. Individual results may vary.

INDICATIONS

LUMRYZ® (sodium oxybate) for extended-release oral suspension is a prescription medicine used to treat the following symptoms in patients 7 years of age and older with narcolepsy:

- sudden onset of weak or paralyzed muscles (cataplexy)
- excessive daytime sleepiness (EDS)

IMPORTANT SAFETY INFORMATION

WARNING: Taking LUMRYZ® (sodium oxybate) with other central nervous system (CNS) depressants such as medicines used to make you fall asleep, including opioid analgesics, benzodiazepines, sedating antidepressants, antipsychotics, sedating anti-epileptic medicines, general anesthetics, muscle relaxants, alcohol, or street drugs, may cause serious medical problems, including trouble breathing (respiratory depression), low blood pressure (hypotension), changes in alertness (drowsiness), fainting (syncope), and death.

The active ingredient of LUMRYZ (sodium oxybate) is a form of gamma hydroxybutyrate (GHB), a controlled substance. Abuse or misuse of illegal GHB alone or with other CNS depressants (drugs that cause changes in alertness or consciousness) have caused serious side effects. These effects include seizures, trouble breathing (respiratory depression), changes in alertness (drowsiness), coma, and death. Call your doctor right away if you have any of these serious side effects.

Because of these risks, LUMRYZ is available only by prescription and filled through certified pharmacies in the LUMRYZ REMS program. You must be enrolled in the LUMRYZ REMS to receive LUMRYZ. Further information is available at www.LUMRYZREMS.com or by calling 1-877-453-1029.

Please see additional [Important Safety Information](#) throughout, and full [Prescribing Information](#), including Boxed Warning and [Medication Guide](#).

Narcolepsy is a chronic, 24/7 sleep-wake disorder



Narcolepsy affects the brain's ability to control your sleep-wake cycles, disrupting both your days and nights

Two common symptoms of narcolepsy are excessive daytime sleepiness and cataplexy.

There are 2 types of narcolepsy:

Narcolepsy type 1:
Narcolepsy with cataplexy

Narcolepsy type 2:
Narcolepsy without cataplexy



Excessive Daytime Sleepiness (EDS):

A persistent feeling of sleepiness that disrupts your day

- Usually the first symptom people notice
- Can occur at random or during less active situations, such as when watching TV
- Can happen no matter how much you slept the night before



Cataplexy:

Sudden attacks of muscle weakness, often triggered by strong emotions

- Can be mild and feel like knees buckling, or as severe as full-body paralysis
- Usually lasts for a few seconds or minutes
- People remain entirely conscious, even if they are temporarily unable to speak or move

While everyone with narcolepsy has some level of daytime sleepiness, not everyone will experience cataplexy

IMPORTANT SAFETY INFORMATION (cont'd)

Do not take LUMRYZ if you take or your child takes other sleep medicines or sedatives (medicines that cause sleepiness), drink alcohol, or have a rare problem called succinic semialdehyde dehydrogenase deficiency.

Narcolepsy may sometimes feel like an "invisible condition"



It can take up to 19 years from when symptoms first start to receive an accurate diagnosis. Some people with narcolepsy may even experience social stigma from those who don't understand the condition.



"Trying to get a diagnosis? I mean, this was a 15-year-long journey, so it was definitely discouraging at times."

LAUREN

living with narcolepsy

Lauren was compensated by Alkermes.

Treatment may help you reclaim some of your day from the symptoms of narcolepsy

It's important to share all of your narcolepsy symptoms, experiences, and goals with your healthcare provider so that you can work together to find the best treatment for you

IMPORTANT SAFETY INFORMATION (cont'd)

Keep LUMRYZ in a safe place to prevent abuse and misuse. Selling or giving away LUMRYZ may harm others and is against the law. Tell your doctor if you or your child have ever abused or been dependent on alcohol, prescription medicines, or street drugs.

Lumryz[®]
(sodium oxybate)
for extended-release
oral suspension

Please see additional [Important Safety Information](#) throughout, and full [Prescribing Information](#), including Boxed Warning and [Medication Guide](#).



LUMRYZ® is the first and only extended-release oxybate

FDA-approved in patients 7 years of age and older with narcolepsy to treat:

- sudden onset of weak or paralyzed muscles (cataplexy)
- excessive daytime sleepiness (EDS)

About oxybate therapy:

- Oxybates are designed to work while you sleep
- Oxybates are the only class of narcolepsy treatments that **you take at night to help improve daytime narcolepsy symptoms**



The exact way LUMRYZ works for the treatment of EDS and cataplexy in patients with narcolepsy is unknown.

IMPORTANT SAFETY INFORMATION (cont'd)


Anyone who takes LUMRYZ should not do anything that requires them to be fully awake or is dangerous, including driving a car, using heavy machinery, or flying an airplane, for at least six (6) hours after taking LUMRYZ. Those activities should not be done until you know how LUMRYZ affects you.

Extended-release LUMRYZ® is designed differently

LUMRYZ is dosed once at bedtime

LUMRYZ contains a blend of granules that work in 2 ways

- **Immediate-release** — granules start working as you fall asleep
- **Controlled-release** — granules start working later while you sleep



Each dosage strength comes in a different color packet.

The active ingredient in LUMRYZ is sodium oxybate

After taking LUMRYZ before bed, the extended-release formulation allows the amount of medicine in your body to **gradually decline toward your waking hours**

IMPORTANT SAFETY INFORMATION (cont'd)

Falling asleep quickly, including while standing or while getting up from the bed, has led to falls with injuries that have required some people to be hospitalized.

LUMRYZ can cause serious side effects, including the following:

- **Breathing problems**, including slower breathing, trouble breathing, and/or short periods of not breathing while sleeping (eg, sleep apnea). People who already have breathing or lung problems have a higher chance of having breathing problems when they take LUMRYZ.

Please see additional [Important Safety Information](#) throughout, and full [Prescribing Information](#), including Boxed Warning and [Medication Guide](#).

EXTENDED-RELEASE
Lumryz®
(sodium oxybate)
for extended-release
oral suspension ©

LUMRYZ® was proven to reduce daytime symptoms of narcolepsy

LUMRYZ was studied in a 13-week clinical trial

LUMRYZ was studied for the treatment of EDS and cataplexy in a double-blind, placebo-controlled clinical trial of 212 people with narcolepsy.

- Half of the people (107 people) took LUMRYZ
- The other half (105 people) took placebo (a substitute that had no medicine in it)

A look at people in the trial:

Ages 16 to 72 years

The average age was 31 years old

76%

had narcolepsy with cataplexy, also known as narcolepsy type 1

24%

had narcolepsy without cataplexy, also known as narcolepsy type 2

Results were measured at Week 3 (88 people taking the 6 g dose of LUMRYZ), Week 8 (77 people taking the 7.5 g dose of LUMRYZ), and Week 13 (69 people taking the 9 g dose of LUMRYZ) and were compared with the people taking placebo. Those receiving LUMRYZ initially received 4.5 g for 1 week, followed by 6 g for Weeks 2 to 3, 7.5 g for Weeks 4 to 8, and then 9 g for Weeks 9 to 13.

EDS, excessive daytime sleepiness.

IMPORTANT SAFETY INFORMATION (cont'd)

- **Mental health problems**, including confusion, seeing or hearing things that are not real (hallucinations), unusual or disturbing thoughts (abnormal thinking), feeling anxious or upset, depression, thoughts of killing yourself or trying to kill yourself, increased tiredness, feelings of guilt or worthlessness, and difficulty concentrating. Tell your doctor if you or your child have or had depression or have tried to harm yourself. **Call your doctor right away if you or your child have symptoms of mental health problems or a change in weight or appetite.**

Results from the LUMRYZ® clinical study

People taking LUMRYZ (9 g) at Week 13 experienced*:

Reduced EDS



People on LUMRYZ stayed awake **3x longer during daytime wakefulness tests¹** (compared to 1x on placebo)

For 68 people taking LUMRYZ, wakefulness increased by an average of about 11 minutes during a daytime wakefulness test compared to start of treatment. For 78 people taking placebo, wakefulness increased by an average of about 5 minutes compared to start of treatment. People were able to stay awake for 5 minutes before receiving LUMRYZ compared to 15.5 minutes at Week 13.

Less cataplexy



57% fewer weekly cataplexy attacks for people with narcolepsy type 1 (compared to 25% taking placebo)

At Week 13, 55 people taking LUMRYZ had about 12 fewer cataplexy attacks per week vs where they started, compared to about 5 fewer per week in 62 people taking placebo.

Improved symptoms



73% were rated by clinicians to be much or very much improved[‡] (compared to 32% taking placebo)

At Week 13 in 69 people taking LUMRYZ and 79 people taking placebo compared to the start of the study.

*As seen in people taking the 9 g dose of LUMRYZ and compared to baseline results at the start of the trial.

¹Daytime wakefulness was measured after an overnight sleep study. People completed 5 daytime test sessions, each about 2 hours apart. During each 30-minute session, people were instructed to stay awake while seated in a quiet and comfortable room. The test measured how long they stayed awake before falling asleep.

[‡]Healthcare providers rated each person's overall change in symptoms on a 7-item scale, ranging from "very much worse" to "very much improved."

IMPORTANT SAFETY INFORMATION (cont'd)

- **Sleepwalking.** Sleepwalking can cause injuries. Call your doctor if you or your child start sleepwalking.

Tell your doctor if you or your child are on a salt-restricted diet or have high blood pressure, heart failure, or kidney problems. LUMRYZ contains a lot of sodium (salt) and may not be right for you.

Please see additional [Important Safety Information](#) throughout, and full [Prescribing Information](#), including Boxed Warning and [Medication Guide](#).


(sodium oxybate)
for extended-release
oral suspension 

Common side effects of LUMRYZ®

Starting a new medication can raise questions about side effects. Because LUMRYZ can cause serious side effects, it's important to talk with your healthcare provider about these risks and what they may mean for you before starting treatment.

The most common side effects reported by adults in the clinical trial were:

Nausea • Dizziness • Bedwetting • Headache • Vomiting

Side effects typically occurred when people started a new dose. Generally, the side effects then declined over time while staying on the same dose. You should always report any side effects you may be experiencing to your healthcare provider while taking LUMRYZ.

The most common side effects in pediatric patients were*:

- Nausea
- Headache
- Dizziness
- Bedwetting
- Decreased weight
- Sleepwalking
- Vomiting
- Decreased appetite

*As shown in a trial for twice-nightly sodium oxybate. LUMRYZ has not been studied in pediatric patients.

Side effects may increase when taking higher doses of LUMRYZ.

These are not all the possible side effects of LUMRYZ. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

LUMRYZ may not be appropriate for some people with narcolepsy. Your healthcare provider can help determine if LUMRYZ is a good fit for you.

How to take LUMRYZ®: Make LUMRYZ part of your bedtime routine

LUMRYZ comes in single-dose premeasured packets that you mix with water



Taking LUMRYZ

[Watch this step-by-step video](#) on how to prepare, shake, and take LUMRYZ.

These instructions are not complete. Please see [Instructions for Use](#) for complete administration directions.



If you like, you can mix in a calorie-free drink mix or flavored water enhancer, such as Crystal Light® or Mio® Liquid Water Enhancer.



Packets also offer simple, convenient travel. Pack the number of dose packets you will need for your trip.



Visit [LUMRYZ.com](https://lumryz.com) to watch personal stories from people living with narcolepsy and treating with LUMRYZ

“Since starting LUMRYZ, I feel more awake for my morning classes. I don't have huge periods of time where I take strong dips into feeling sleepy.”

SYDNEY

living with narcolepsy and treating with LUMRYZ

Sydney was compensated by Alkermes.
Individual results may vary.

Please see additional [Important Safety Information](#) throughout, and full [Prescribing Information](#), including Boxed Warning and [Medication Guide](#).

Lumryz®
(sodium oxybate)
for extended-release
oral suspension ©

LUMRYZ® has strong coverage for commercially insured patients^{1,*}



RYZUP
SUPPORT SERVICES

RYZUP Support Services provides several programs that support access to LUMRYZ

LUMRYZ Co-pay Program:

With the LUMRYZ co-pay program, most patients with commercial insurance pay a **\$0 co-pay** for LUMRYZ.[†]

- Your specialty pharmacy will automatically apply co-pay savings if your commercial insurance qualifies

LUMRYZ Bridge Program:

If you are already taking LUMRYZ and have an interruption in coverage due to your insurance, you may be eligible to receive your medication at no cost.[‡]

LUMRYZ Quick Start Program:

If you are starting LUMRYZ and there is an initial denial or delay in your insurance approving your treatment, you may be eligible to receive your medication at no cost.[‡]

Patient Assistance Program (PAP):

If you are uninsured or underinsured, you may be eligible to receive LUMRYZ at no cost.[§]

¹Data on file. Alkermes, Inc.

*Prior authorization may be required. This information is current as of 07/2026 and is subject to change. This is not a guarantee of payment coverage or reimbursement. Actual coverage and reimbursement decisions are made by the health plan. Contact the health plan for complete and current information regarding coverage of LUMRYZ.

[†]This offer is valid only for patients who have commercial insurance and a qualifying LUMRYZ prescription. Offer not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs. Maximum benefit limits per prescription and annual benefit limits ("Annual Program Maximum") per individual apply. Patients' out-of-pocket expenses may vary. Additional terms and conditions apply. [Download the full terms and conditions](#) of the co-pay program.

[‡]Applies only to eligible, commercially insured patients. Additional terms and conditions apply.

[§]PAP application required. Patient must meet certain financial and other criteria.

Get personalized support throughout your LUMRYZ® journey with RYZUP Support Services

For each step of your treatment journey, dedicated RYZUP Support Services Nurse Care Navigators (NCNs) will be there for you*

Your NCN team will support your access to LUMRYZ and is available to answer product questions throughout your treatment. They will:

- ✓ Follow up to capture any missing information or signatures to help complete your enrollment
- ✓ Answer questions you have about LUMRYZ (including LUMRYZ savings and access programs)
- ✓ Provide educational information and resources
- ✓ Consult with your healthcare and insurance providers to help determine coverage and your out-of-pocket costs

If you'd like to learn more about RYZUP Support Services, you can reach the team at **1-844-485-7636 from 8:00 AM to 8:00 PM Eastern Time, Monday through Friday.**

Once you start LUMRYZ, your specialty pharmacy is also a resource for you and has 24/7 pharmacist support

*NCNs do not provide medical advice or manage symptoms. You should discuss medical questions or concerns with your healthcare provider.

Get ready for your LUMRYZ journey

Once you and your healthcare provider have decided LUMRYZ is right for you, it's helpful to have a clear picture of what comes next. Visit [MyLUMRYZ.com](https://mylumryz.com) for an overview of the typical stages of your journey with LUMRYZ.

Please see additional [Important Safety Information](#) throughout, and full [Prescribing Information](#), including Boxed Warning and [Medication Guide](#).

**Real connection. Real support.
One-on-one.**



Lauren and Melanie, LUMRYZ® Mentors

Lumryz®

(sodium oxybate) for extended-release
oral suspension 4.5 | 6 | 7.5 | 9 g

MENTOR PROGRAM

For many, the treatment journey may feel uncertain and confusing, but it's important to remember that you're not alone.

The phone-based LUMRYZ Mentor Program connects you with someone who may understand what you're going through.

When you join a one-on-one conversation with a LUMRYZ Mentor, you have the opportunity to ask questions, and they will share their personal experiences about:

- Living with this condition
- Starting and staying on LUMRYZ
- Managing day-to-day life with narcolepsy


**Connect with a LUMRYZ®
Mentor today**

Whether you're exploring your options or already being treated with LUMRYZ, speaking with a real person being treated with LUMRYZ can offer honest insights, lived experiences, and encouragement that may help you feel more confident during your journey.



To learn more about the LUMRYZ Mentor Program and to schedule a call with a mentor, please call 1-888-209-5105 or visit LumryzMentors.com to register for the program.

Must be 18 years of age or older to participate.



Visit LUMRYZ.com to hear more from others about their journey with narcolepsy and their experience treating with LUMRYZ.

Melanie, Tyler, and Lauren, LUMRYZ Mentors

Note: Mentors do not provide medical advice. You should discuss medical questions or concerns with your healthcare provider.

Please see additional [Important Safety Information](#) throughout, and full [Prescribing Information](#), including Boxed Warning and [Medication Guide](#).

IMPORTANT SAFETY INFORMATION

INDICATIONS

LUMRYZ (sodium oxybate) for extended-release oral suspension is a prescription medicine used to treat the following symptoms in patients 7 years of age and older with narcolepsy:

- sudden onset of weak or paralyzed muscles (cataplexy)
- excessive daytime sleepiness (EDS)

IMPORTANT SAFETY INFORMATION

WARNING: Taking LUMRYZ® (sodium oxybate) with other central nervous system (CNS) depressants such as medicines used to make you fall asleep, including opioid analgesics, benzodiazepines, sedating antidepressants, antipsychotics, sedating anti-epileptic medicines, general anesthetics, muscle relaxants, alcohol, or street drugs, may cause serious medical problems, including trouble breathing (respiratory depression), low blood pressure (hypotension), changes in alertness (drowsiness), fainting (syncope), and death.

The active ingredient of LUMRYZ (sodium oxybate) is a form of gamma hydroxybutyrate (GHB), a controlled substance. Abuse or misuse of illegal GHB alone or with other CNS depressants (drugs that cause changes in alertness or consciousness) have caused serious side effects. These effects include seizures, trouble breathing (respiratory depression), changes in alertness (drowsiness), coma, and death. Call your doctor right away if you have any of these serious side effects.

Because of these risks, LUMRYZ is available only by prescription and filled through certified pharmacies in the LUMRYZ REMS program. You must be enrolled in the LUMRYZ REMS to receive LUMRYZ. Further information is available at www.LUMRYZREMS.com or by calling 1-877-453-1029.

Do not take LUMRYZ if you take or your child takes other sleep medicines or sedatives (medicines that cause sleepiness), drink alcohol, or have a rare problem called succinic semialdehyde dehydrogenase deficiency.

Keep LUMRYZ in a safe place to prevent abuse and misuse. Selling or giving away LUMRYZ may harm others and is against the law. Tell your doctor if you or your child have ever abused or been dependent on alcohol, prescription medicines, or street drugs.

Anyone who takes LUMRYZ should not do anything that requires them to be fully awake or is dangerous, including driving a car, using heavy machinery, or flying an airplane, for at least six (6) hours after taking LUMRYZ. Those activities should not be done until you know how LUMRYZ affects you.

Falling asleep quickly, including while standing or while getting up from the bed, has led to falls with injuries that have required some people to be hospitalized.

LUMRYZ can cause serious side effects, including the following:

- **Breathing problems, including** slower breathing, trouble breathing, and/or short periods of not breathing while sleeping (eg, sleep apnea). People who already have breathing or lung problems have a higher chance of having breathing problems when they take LUMRYZ.
- **Mental health problems, including** confusion, seeing or hearing things that are not real (hallucinations), unusual or disturbing thoughts (abnormal thinking), feeling anxious or upset, depression, thoughts of killing yourself or trying to kill yourself, increased tiredness, feelings of guilt or worthlessness, and difficulty concentrating. Tell your doctor if you or your child have or had depression or have tried to harm yourself. **Call your doctor right away if you or your child have symptoms of mental health problems or a change in weight or appetite.**
- **Sleepwalking.** Sleepwalking can cause injuries. Call your doctor if you or your child start sleepwalking.

Tell your doctor if you or your child are on a salt-restricted diet or have high blood pressure, heart failure, or kidney problems. LUMRYZ contains a lot of sodium (salt) and may not be right for you.

The most common side effects of LUMRYZ in adults include nausea, dizziness, bedwetting, headache, and vomiting. Your side effects may increase when you take higher doses of LUMRYZ. The most common side effects in children include nausea, bedwetting, vomiting, headache, decreased weight, decreased appetite, dizziness, and sleepwalking.

LUMRYZ can cause physical dependence and craving for the medicine when it is not taken as directed. These are not all the possible side effects of LUMRYZ.

For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full [Prescribing Information](#), including Boxed Warning and [Medication Guide](#).


(sodium oxybate) for extended-release
oral suspension 



Lumryz®
EXTENDED
-RELEASE
(sodium oxybate)
for extended-release
oral suspension

LUMRYZ® CAN HELP YOU FEEL AWAKE FOR MORE DAYTIME MOMENTS

Talk to your doctor about LUMRYZ, the first and only FDA-approved extended-release oxybate for narcolepsy, and visit [LUMRYZ.com](https://www.lumryz.com) to learn more

INDICATIONS

LUMRYZ (sodium oxybate) for extended-release oral suspension is a prescription medicine used to treat the following symptoms in patients 7 years of age and older with narcolepsy:

- sudden onset of weak or paralyzed muscles (cataplexy)
- excessive daytime sleepiness (EDS)

IMPORTANT SAFETY INFORMATION

WARNING: Taking LUMRYZ® (sodium oxybate) with other central nervous system (CNS) depressants such as medicines used to make you fall asleep, including opioid analgesics, benzodiazepines, sedating antidepressants, antipsychotics, sedating anti-epileptic medicines, general anesthetics, muscle relaxants, alcohol, or street drugs, may cause serious medical problems, including trouble breathing (respiratory depression), low blood pressure (hypotension), changes in alertness (drowsiness), fainting (syncope), and death.

The active ingredient of LUMRYZ (sodium oxybate) is a form of gamma hydroxybutyrate (GHB), a controlled substance. Abuse or misuse of illegal GHB alone or with other CNS depressants (drugs that cause changes in alertness or consciousness) have caused serious side effects. These effects include seizures, trouble breathing (respiratory depression), changes in alertness (drowsiness), coma, and death. Call your doctor right away if you have any of these serious side effects.

Because of these risks, LUMRYZ is available only by prescription and filled through certified pharmacies in the LUMRYZ REMS program. You must be enrolled in the LUMRYZ REMS to receive LUMRYZ. Further information is available at [www.LUMRYZREMS.com](https://www.lumryzrems.com) or by calling 1-877-453-1029.

Please see additional [Important Safety Information](#) throughout, and full [Prescribing Information](#), including Boxed Warning and [Medication Guide](#).



LUMRYZ® and RYZUP® are registered trademarks of Flamel Ireland Limited, an affiliate of Alkermes, plc. ALKERMES® and the Alkermes design are registered trademarks of Alkermes, Inc. All other trademarks are the property of their respective owners.
© 2026 Alkermes, Inc. All rights reserved. PM-US-LUM-0870 09/2026